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Abstract Betaine therapy was given for 2 years to a 2-
year-old boy with 5,10-methylenetetrahydrofolate reductase
deficiency. Used as a methyl donor to lower homocysteine
levels through methylation of methionine, betaine has been
reported to be effective in treating homocystinuria. Satis-
factory biochemical and clinical responses were obtained
with the following regimen: betaine started in the newborn
period at increasing doses to reach 1 g given six times a
day. It is suggested that frequent administration of a
moderate dose may provide clinical and biochemical
benefit.
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Abbreviations
MTHFR methylenetetrahydrofolate reductase
tHcy total plasma homocysteine
Introduction
Methylenetetrahydrofolate reductase (MTHFR) converts
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate,
which donates a methyl group to homocysteine to form
methionine. MTHFR deficiency results in elevated homocys-
teine and low methionine levels [6]. Betaine, a methyl donor,
has been shown to successfully lower plasma homocysteine
and normalize methionine in MHTR patients of varying age
and disease severity [1–4, 12]. In this paper, we report an
infant successfully treated with betaine, with emphasis on the
frequency of administration.
Case report
A 4-kg male, the third child of consanguineous parents,
was delivered at 40 weeks of gestation after an
uncomplicated pregnancy. Two siblings died 28 and
16 days; the latter having a positive urinary nitroprusside
reaction. Subsequently, the mother received intramuscular
cyanocobalamaine (1 mg every 2 weeks) and folic acid
(5 mg/day) during pregnancy.
On day 2, the patient developed hyperbilirubinemia,
hypotonia, and lethargy. Total plasma homocysteine (tHcy)
was elevated (155.5 μmol/L [5–15 μmol/L]) and methio-
nine was reduced (13.1 μmol/L [7.9–55.3 μmol/L]).
Urinary homocystine (102 mmol/mol creatinine [0.2–
4 mmol/mol creatinine]) and cystathionine (89 mmol/mol
creatinine [0.1–3 mmol/mol creatinine]) were increased and
urinary nitroprusside testing was positive. Plasma cobala-
min, erythrocyte folate, and organic acid profile were
normal. The metabolite pattern suggested a remethylation
defect and folic acid (10 mg/day), pyridoxine (100 mg/day),
hydroxycobalamine (1 mg/day), and carnitine (300 mg/day;
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Carnitine%30, Santa Farma) were initiated. At 2 months,
betaine anhydrous (100 mg/kg/day, given every 2 h;
Cystadane®, Orphan Europe) was introduced.
No enzyme activity was detectable in fibroblasts (0 nmol
methyl tetrahydrofolate/h/mg protein), confiming a severe
MHTFR deficiency and betaine was increased weekly in
50 mg/kg increments to 3 g/day. Each dose, mixed with
formula, was given nine times per day via nasogastic tube.
From 9 months to 2 years, 6 g betaine/day was adminis-
trated orally with meals in six divided doses, mixed with
food, milk, or juice. The effects of reducing the frequency
to three per day and of increasing the dose to 9 g/day, given
three or six times, on plasma tHcy and methionine were
evaluated (Fig. 1). Reducing the frequency to three per day
increased tHcy from 45 μmol/L (5–15.5 μmol/L) to around
90 mmol/L and decreased methionine levels. Increasing to
more than six per day led to difficulties in administration;
6 g/day of betaine given in six doses provided adequate
control in this patient.
Physical development was normal; however, language
development and motor development were retarded by 3 to
6 months. No vaso-occlusive or thromboembolic events
occurred.
Discussion
The efficacy of betaine treatment in MTHFR deficiency
is established. However, dosage and frequency of
administration are still controversial. One study in
patients with MTHFR deficiency showed peak betaine
concentration after 1 and 2 h with an apparent elimina-
tion half-life of 1 h [7]. A comparison between 12 healthy
males and three patients revealed an increased total plasma
betaine clearance in patients, suggesting that, due to
accelerated distribution and elimination kinetics, patients
may require more frequent dosing to maintain plasma
concentrations [8]. In this paper, mean tHcy levels of
45 µmol/L (5–15.5 µmol/L) were achieved by administra-
tion at short intervals. This is in contrast with data
indicating minimal benefit from exceeding twice-daily
dosing in six patients with classical homocystinuria [5].
In healthy individuals, betaine concentrations are not
affected by age and gender. However, in patients with
MTHFR deficiency and classical homocystinuria, this may
not be the case. Patient age, primary diagnosis, metabolic
status, and duration of treatment may explain such
discrepancies. There is a need for further studies of
betaine in MTHFR deficiency to optimize treatment
modalities.
Additionally, one therapeutic action of betaine is to
increase brain methionine uptake [11]. Increasing plasma
methionine concentration via optimizing betaine therapy
may enhance transportation into the brain [9, 10].
In conclusion, more frequent administration of moderate
doses of betaine in patients with MTHFR deficiency may
provide clinical and biochemical benefits and should be
evaluated further.
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Fig. 1 The mean total homo-
cysteine and methionine in
plasma in relation to daily dose
and frequency of betaine treat-
ment (blood samples were
collected prior to administration
of betaine during the last week
of the each month)
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